



NDA 18-709/S-035

Bristol-Myers Squibb
Attention: Mr. David Silberstein
PO Box 4000
Princeton, NJ 08543-4000

Dear Mr. Silberstein:

Please refer to your supplemental new drug applications dated September 29, 2008 submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Capozide® (captopril/hydrochlorothiazide) 25/15, 50/15, 25/25, 50/25 mg Tablets.

This “changes-being-effected” supplemental application provides for additional information in the **PRECAUTIONS/Drug Interactions** section of the package insert as requested in our letter dated March 3, 2008.

This supplemental new drug application provides for electronic labeling with the following revisions:

1. Under the **PRECAUTIONS/Drug Interactions** subsection, the following interaction has been added:
Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including CAPOZIDE.
2. We also note several editorial revisions throughout the label.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the electronic (SPL) labeling text submitted on September 29, 2008. If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

NDA 18-709/S-035

Page 2

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Alisea Crowley, Pharm.D., RAC
Senior Regulatory Project Manager
(301) 796-1144

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Drug
Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
2/26/2009 10:35:18 AM